A new layer in pharmaceutical performance
Ibumix is developing a formulation platform designed to improve drug absorption, increase efficiency, and unlock the full potential of every dose.
A systematic inefficiency in medicine
Most oral medicines are not fully absorbed.
Therapeutic performance is often limited not by the active ingredient, but by how effectively it is delivered and taken up.
This creates a large and under-addressed inefficiency across pharmaceuticals.
A formulation-first approach
Ibumix is developing advanced formulations and excipient systems designed to improve absorption and bioavailability.
Rather than changing the molecule, we optimise how it is delivered.Drug delivery remains one of the most under-optimised areas in pharmaceuticals.
A platform, not a single product
The Ibumix approach is designed to be applied across multiple active pharmaceutical ingredients and therapeutic areas.
Ibuprofen represents the initial application.
The underlying technology is broader.
Structured scientific development
Ibumix is deploying capital into a focused R&D programme in collaboration with a UK university.
This enables:
- Controlled laboratory testing
- Independent validation
- Generation of high-quality data
SEIS Investment Round
Seed Enterprise Investment Scheme (SEIS). UK tax-advantaged. Up to 50% income tax relief, 50% CGT exemption on gains.
SEIS investment will be allocated across:
- Formulation development and optimisation
- Bioavailability and dissolution testing
- Analytical and experimental data generation
- Early-stage intellectual property development
Defensible by design
Ibumix is building a layered intellectual property strategy alongside its scientific development.
An initial UK and global patent application has been filed covering core aspects of the formulation approach, with additional filings planned to expand protection across applications and use cases.
A critical stage of development
This phase will:
- Validate core technology
- Generate performance data
- Establish the foundation for partnerships and scale
Systematic opportunity
A widespread inefficiency in drug delivery.
Scalable Platform
Applicable across multiple medicines.
Clear pathways to scale
Licensing, partnerships, and integration.
Aligned with UK SEIS investors
- Significant tax efficiency
- Early-stage access to a platform technology
- Exposure to a high-upside, science-led opportunity
Engage with Ibumix
We are currently engaging with a limited number of investors.